Posted by Michael Wonder on 13 Dec 2024
Vir Biotechnology receives FDA breakthrough therapy designation and EMA PRIME designation for tobevibart and elebsiran in chronic hepatitis delta
12 December 2024 - Phase 3 ECLIPSE registrational program in chronic hepatitis delta to begin in the first half of 2025.
Vir Biotechnology today announced that tobevibart and elebsiran have received US FDA breakthrough therapy designation and EMA Priority Medicines (PRIME) designation for the treatment of chronic hepatitis delta.
